Lilly backs OrsoBio's $60M Series A for PhII trials in obesity and NASH
OrsoBio, a biotech focused on obesity and metabolic disorders, is getting financial support from one of the leading drugmakers in the field as Eli Lilly helps back its $60 million Series A round.
OrsoBio, based in Menlo Park, CA, is an amalgamation of assets from Gilead, Shionogi, Phenex Pharmaceuticals and Astellas, and it already has candidates in human testing or clinical plans for obesity, type 2 diabetes, nonalcoholic steatohepatitis, as well as other inflammatory liver and kidney disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.